Acepodia logo

Acepodia

POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER

49 employees · est. 2016 · Alameda, United States

VS
IN8bio logo

IN8bio

Developing Next-Generation Gamma-Delta T Cell Engagers and Cellular Therapies for Cancer & Autoimmune Disease

25 employees · est. 2016 · New York, United States

Side-by-Side Comparison

Acepodia IN8bio
Founded
2016 2016
Headquarters
Alameda, United States New York, United States
Employees
49 25
Industry
Biotechnology, Health Care, Health and Wellness Biotechnology, Health Care, Health and Wellness
Funding Stage
Series D Unknown
Total Funding
$256.00M $209.96M
Funding Rounds
3 8
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Acepodia, Clinical-stage, Cancer Cell Immunotherapy, Off-the-shelf, NK Cells, Antibody-cell Conjugation, Cell Therapy, Oncology, Immune Effector Cells, Solid Tumors, Hematologic Cancers, Immunotherapeutic Strategies, Interdisciplinary Technology Not tracked yet
Website
acepodia.com in8bio.com
Acepodia logo

About Acepodia

Acepodia is a clinical-stage biotechnology company founded in 2016, with a focus on developing innovative and highly effective cell therapies for cancer patients. The company's slogan, "POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER," encapsulates its mission. Acepodia leverages its An...

IN8bio logo

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. The company leverages its expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific ma...

We will tell you when either one moves

BounceWatch watches Acepodia and IN8bio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Acepodia and IN8bio — by email.

Frequently Asked Questions

Acepodia — POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER. IN8bio — Developing Next-Generation Gamma-Delta T Cell Engagers and Cellular Therapies for Cancer & Autoimmune Disease. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Acepodia has raised $256.00M while IN8bio has raised $209.96M.
Acepodia and IN8bio operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Acepodia with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Acepodia on 11 Sep 2024, and IN8bio on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy